{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:45:08Z","timestamp":1791042308866,"version":"4.1.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1097\/bor.0b013e32833f0fc7","type":"journal-article","created":{"date-parts":[[2010,9,4]],"date-time":"2010-09-04T04:22:19Z","timestamp":1283574139000},"page":"644-650","source":"Crossref","is-referenced-by-count":59,"title":["Statin myopathy: a review of recent progress"],"prefix":"10.1097","volume":"22","author":[{"given":"Andrew L","family":"Mammen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony A","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210128","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"R3-6-20210128","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/01.bor.0000245730.25383.97","article-title":"Statin myopathy: an update","volume":"18","author":"Christopher-Stine","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"R4-6-20210128","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/BOR.0b013e328010c559","article-title":"Myotoxicity associated with lipid-lowering drugs","volume":"19","author":"Baer","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"R5-6-20210128","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"R6-6-20210128","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0002-9149(02)02449-9","article-title":"Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia [ExPRESS FH])","volume":"90","author":"De Sauvage Nolting","year":"2002","journal-title":"Am J Cardiol"},{"key":"R7-6-20210128","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"R8-6-20210128","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1023\/B:CARD.0000015861.26111.ab","article-title":"A comprehensive description of muscle symptoms associated with lipid-lowering drugs","volume":"17","author":"Franc","year":"2003","journal-title":"Cardiovasc Drugs Ther"},{"key":"R9-6-20210128","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/106002809502907-818","article-title":"Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia","volume":"29","author":"Hsu","year":"1995","journal-title":"Ann Pharmacother"},{"key":"R10-6-20210128","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/pds.1603","article-title":"The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care","volume":"17","author":"Garcia-Rodriguez","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R11-6-20210128","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/pds.1602","article-title":"The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases","volume":"17","author":"Garcia-Rodriguez","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R12-6-20210128","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/fampra\/cmp006","article-title":"Statin use and its association with musculoskeletal symptoms: a cross-sectional study in primary care settings","volume":"26","author":"Mosshammer","year":"2009","journal-title":"Fam Pract"},{"key":"R13-6-20210128","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s11606-008-0636-7","article-title":"Prevalence of musculoskeletal pain and statin use","volume":"23","author":"Buettner","year":"2008","journal-title":"J Gen Intern Med"},{"key":"R14-6-20210128","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.clinthera.2007.08.022","article-title":"Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients","volume":"29","author":"Nichols","year":"2007","journal-title":"Clin Ther"},{"key":"R15-6-20210128","doi-asserted-by":"crossref","first-page":"e2522","DOI":"10.1371\/journal.pone.0002522","article-title":"Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991\u20132006","volume":"3","author":"Molokhia","year":"2008","journal-title":"PLoS One"},{"key":"R16-6-20210128","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.amjcard.2008.08.014","article-title":"Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials","volume":"102","author":"Wlodarczyk","year":"2008","journal-title":"Am J Cardiol"},{"key":"R17-6-20210128","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1472-6904-9-6","article-title":"MRC\/BHF Heart Protection Study Collaborative Group, Armitage J, Bowman L, et al. Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people.","volume":"9","year":"2009","journal-title":"BMC Clin Pharmacol"},{"key":"R18-6-20210128","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.clinthera.2007.02.008","article-title":"Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy","volume":"29","author":"Silva","year":"2007","journal-title":"Clin Ther"},{"key":"R19-6-20210128","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"R20-6-20210128","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"R21-6-20210128","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"De Lemos","year":"2004","journal-title":"JAMA"},{"key":"R22-6-20210128","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"R23-6-20210128","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1345\/aph.1M410","article-title":"Does simvastatin cause more myotoxicity compared with other statins?","volume":"43","author":"Backes","year":"2009","journal-title":"Ann Pharmacother"},{"key":"R24-6-20210128","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"R25-6-20210128","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1001\/jama.287.24.3215","article-title":"Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial","volume":"287","author":"Serruys","year":"2002","journal-title":"JAMA"},{"key":"R26-6-20210128","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy: a genomewide study.","volume":"359","author":"SEARCH Collaborative Group, Link","year":"2008","journal-title":"N Engl J Med"},{"key":"R27-6-20210128","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"key":"R28-6-20210128","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3132\/dvdr.2008.029","article-title":"The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"5","author":"Newman","year":"2008","journal-title":"Diab Vasc Dis Res"},{"key":"R29-6-20210128","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1345\/aph.1K604","article-title":"Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance","volume":"42","author":"Backes","year":"2008","journal-title":"Ann Pharmacother"},{"key":"R30-6-20210128","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R31-6-20210128","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/pds.1711","article-title":"Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors","volume":"18","author":"Rowan","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R33-6-20210128","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.lfs.2008.01.021","article-title":"Role of multidrug resistance-associated protein-1 transporter in statin-induced myopathy","volume":"82","author":"Dorajoo","year":"2008","journal-title":"Life Sci"},{"key":"R34-6-20210128","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.amjcard.2008.01.041","article-title":"Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials","volume":"101","author":"Kashani","year":"2008","journal-title":"Am J Cardiol"},{"key":"R35-6-20210128","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.20567","article-title":"Genetic risk factors associated with lipid-lowering drug-induced myopathies","volume":"34","author":"Vladutiu","year":"2006","journal-title":"Muscle Nerve"},{"key":"R36-6-20210128","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1017\/S0317167100007630","article-title":"Metabolic myopathies discovered during investigations of statin myopathy","volume":"35","author":"Baker","year":"2008","journal-title":"Can J Neurol Sci"},{"key":"R37-6-20210128","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMc0908215","article-title":"Neuromuscular symptoms and elevated creatine kinase after statin withdrawal","volume":"362","author":"Echaniz-Laguna","year":"2010","journal-title":"N Engl J Med"},{"key":"R38-6-20210128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.metabol.2008.09.019","article-title":"Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?","volume":"58","author":"Glueck","year":"2009","journal-title":"Metabolism"},{"key":"R39-6-20210128","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nmd.2006.10.007","article-title":"Progressive myopathy with up-regulation of MHC-I associated with statin therapy","volume":"17","author":"Needham","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"R40-6-20210128","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins","volume":"41","author":"Grable-Esposito","year":"2010","journal-title":"Muscle Nerve"},{"key":"R42-6-20210128","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/CIRCRESAHA.109.203596","article-title":"Human skeletal muscle drug transporters determine local exposure and toxicity of statins","volume":"106","author":"Knauer","year":"2010","journal-title":"Circ Res"},{"key":"R43-6-20210128","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0021-9150(01)00613-X","article-title":"3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation","volume":"161","author":"Blanco-Colio","year":"2002","journal-title":"Atherosclerosis"},{"key":"R44-6-20210128","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.taap.2004.04.010","article-title":"Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone","volume":"200","author":"Johnson","year":"2004","journal-title":"Toxicol Appl Pharmacol"},{"key":"R45-6-20210128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5551\/jat.E551","article-title":"Investigation of gene expression in C(2)C(12) myotubes following simvastatin application and mechanical strain","volume":"16","author":"Yu","year":"2009","journal-title":"J Atheroscler Thromb"},{"key":"R46-6-20210128","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1211\/jpp.57.11.0014","article-title":"Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein","volume":"57","author":"Matzno","year":"2005","journal-title":"J Pharm Pharmacol"},{"key":"R47-6-20210128","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1096\/fj.07-8713com","article-title":"Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers","volume":"21","author":"Sakamoto","year":"2007","journal-title":"FASEB J"},{"key":"R48-6-20210128","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1254\/jphs.08238FP","article-title":"Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats","volume":"109","author":"Itagaki","year":"2009","journal-title":"J Pharmacol Sci"},{"key":"R49-6-20210128","first-page":"3940","article-title":"The muscle-specific ubiquitin ligase atrogin-1\/MAFbx mediates statin-induced muscle toxicity","volume":"117","author":"Hanai","year":"2007","journal-title":"J Clin Invest"},{"key":"R50-6-20210128","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1096\/fj.08-128843","article-title":"Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect","volume":"23","author":"Cao","year":"2009","journal-title":"FASEB J"},{"key":"R51-6-20210128","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1211\/jpp.61.06.0011","article-title":"Synergistic action of statins and nitrogen-containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblasts","volume":"61","author":"Nishiguchi","year":"2009","journal-title":"J Pharm Pharmacol"},{"key":"R52-6-20210128","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.bcp.2009.12.007","article-title":"Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy","volume":"79","author":"Mullen","year":"2010","journal-title":"Biochem Pharmacol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0b013e32833f0fc7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:39:24Z","timestamp":1786041564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-201011000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e32833f0fc7","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}